Researchers from the U.S. Department of Defense will evaluate MicroCures’ lead product, siFi2, in animal models with spinal cord injuries.
Intended to improve recovery after trauma, siFi2 is a small interfering ribonucleic acid therapeutic that is applied topically.
Spearheaded by Kimberly Byrnes, PhD, of the Uniformed Services University of the Health Sciences in Bethesda, Md., researchers will explore the use of siFi2 in driving axon regeneration and functional recovery.
More articles on biologics:
Stryker ranks No. 8 in Fortune’s 100 best workplaces
Wuhan neurosurgeon, hospital director dies from coronavirus, death toll rises to 1,800+
Medtronic reports spine revenue up 3%, hurt by low BMP sales: 7 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
